DESCRIPTION
RAGILTM is a preparation of Rasagiline. Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease. The results of a clinical trial designed to examine the effects of Rasagiline on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of Rasagiline. The selectivity for inhibiting MAO-B diminishes in a dose-related manner.